Oslo, Norway, October 28, 2019 PCI Biotech (OSE:PCIB), a clinical-stage company developing innovative therapeutics that address significant unmet medical needs, today announced that it will present the company’s vaccine technology, fimaVACC, at the World Vaccine Congress Europe.
The presentation is named “fimaVACC – a novel technology for enhancing cellular immune responses with protein and peptide-based vaccines” and will focus on fimaVACC’s multiple development opportunities. PCI Biotech will be represented by Anders Høgset (CSO) and the presentation will be given under the ‘New Technology’ part of the congress, on October 29 at 17:45 CET. The presentation will be made available on PCI Biotech’s website under “Other presentations”.
The World Vaccine Congress Europe is a multifaceted conference experience and the presenters are disruptors and visionary industry leaders from the biopharma industry, selected for their relevance, dynamism and insight. The event is taking place at Palau de Congressos de Catalunya, Barcelona, Spain October 28 – 31, 2019.
About PCI Biotech
PCI Biotech is a biopharmaceutical company focusing on development and commercialisation of novel therapies for the treatment of cancer through its innovative photochemical internalisation (PCI) technology platform. PCI is applied to three distinct anticancer paradigms: fimaCHEM (enhancement of chemotherapeutics for localised treatment of cancer), fimaVACC (T-cell induction technology for therapeutic vaccination), and fimaNAc (nucleic acid therapeutics delivery).
Photochemical internalisation induces triggered endosomal release that is used to unlock the true potential of a wide array of therapeutic modalities. The company’s lead programme fimaCHEM consists of a pivotal study in bile duct cancer, an orphan indication with a high unmet need and without approved products. fimaVACC applies a unique mode of action to enhance the essential cytotoxic effect of therapeutic cancer vaccines, which works in synergy with several other state-of-the-art vaccination technologies. fimaNAc utilises the endosomal release to provide intracellular delivery of nucleic acids, such as mRNA and RNAi therapeutics, thereby addressing one of the major bottlenecks facing this emerging and promising field.
PCI Biotech Holding ASA, Ullernchausséen 64, N-0379 Oslo, Norway.
Ronny Skuggedal, CFO, firstname.lastname@example.org, Mobile: +47 9400 5757.
This announcement may contain forward-looking statements, which as such are not historical facts, but are based upon various assumptions, many of which are based, in turn, upon further assumptions. These assumptions are inherently subject to significant known and unknown risks, uncertainties and other important factors. Such risks, uncertainties, contingencies and other important factors could cause actual events to differ materially from the expectations expressed or implied in this announcement by such forward-looking statements. PCI Biotech disclaims any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.